Patients with peripheral artery disease (PAD) often experience significant walking difficulties, and there are limited therapies available to improve their mobility. Investigation made through the STRIDE (Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease) trial focused on semaglutide, a drug known for promoting weight loss, reducing inflammation, and lowering the risk of heart attack or stroke, to determine if it could enhance the functional abilities of PAD patients.

In this interview, Drs. Alison Bailey and Marc Bonaca discuss how the STRIDE trial data supports the use of semaglutide for individuals with PAD and type 2 diabetes, highlighting its cardiometabolic, cardiovascular, and kidney benefits, as well as its ability to improve function, symptoms, and overall quality of life.

Related References:

1. McDermott MM, Sufit R, Domanchuk KJ, Volpe NJ, Kosmac K, Peterson CA, Zhao L, Tian L, Zhang D, Xu S, Ismaeel A, Ferrucci L, Parekh ND, Lloyd-Jones D, Kramer CM, Leeuwenburgh C, Ho K, Criqui MH, Polonsky T, Guralnik JM, Kibbe MR. Hepatocyte growth factor for walking performance in peripheral artery disease. J Vasc Surg. 2025 Jan 6:S0741-5214(24)02320-6. doi: 10.1016/j.jvs.2024.12.124. Epub ahead of print. PMID: 39778757.
2. McDermott MM, Martens CR, Domanchuk KJ, Zhang D, Peek CB, Criqui MH, Ferrucci L, Greenland P, Guralnik JM, Ho KJ, Kibbe MR, Kosmac K, Lloyd-Jones D, Peterson CA, Sufit R, Tian L, Wohlgemuth S, Zhao L, Zhu P, Leeuwenburgh C. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024 Jun 13;15(1):5046. doi: 10.1038/s41467-024-49092-5. Erratum in: Nat Commun. 2024 Aug 12;15(1):6890. doi: 10.1038/s41467-024-51289-7. PMID: 38871717; PMCID: PMC11176364.